Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Update

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a significant decline in short interest in the month of July. As of July 15th, there was short interest totaling 5,761 shares, a decline of 65.5% from the June 30th total of 16,698 shares. Currently, 0.3% of the shares of the company are short sold. Based on an average daily trading volume, of 17,142 shares, the days-to-cover ratio is presently 0.3 days.

Wall Street Analysts Forecast Growth

A number of analysts have commented on BOLT shares. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. Rodman & Renshaw began coverage on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. They set a “buy” rating and a $22.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $34.67.

Bolt Biotherapeutics Stock Up 1.3%

NASDAQ BOLT opened at $4.02 on Wednesday. Bolt Biotherapeutics has a 52 week low of $3.75 and a 52 week high of $7.20. The company has a quick ratio of 3.51, a current ratio of 3.51 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $7.72 million, a P/E ratio of -0.25 and a beta of 1.16. The stock’s 50-day moving average price is $4.37 and its 200-day moving average price is $4.80.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($4.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.85) by ($1.46). Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 100.89%. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $1.50 million. On average, equities research analysts predict that Bolt Biotherapeutics will post -11.1 earnings per share for the current year.

Hedge Funds Weigh In On Bolt Biotherapeutics

A number of hedge funds have recently modified their holdings of BOLT. Squarepoint Ops LLC increased its stake in shares of Bolt Biotherapeutics by 19.8% in the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after purchasing an additional 2,448 shares in the last quarter. Shay Capital LLC purchased a new position in shares of Bolt Biotherapeutics during the 3rd quarter valued at $85,000. Susquehanna International Group LLP purchased a new position in shares of Bolt Biotherapeutics during the 3rd quarter valued at $89,000. Nano Cap New Millennium Growth Fund L P bought a new position in Bolt Biotherapeutics in the 4th quarter worth $112,000. Finally, Renaissance Technologies LLC boosted its holdings in Bolt Biotherapeutics by 40.3% in the 1st quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock worth $312,000 after buying an additional 22,200 shares during the period. 86.70% of the stock is currently owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.